SRSF2 and myelodysplastic syndrome: In this study focusing on DA-eligible lower-risk MDS patients, gene mutations frequently observed in MDS were found in SF3B1 (30.4%), TET2 (25.3%), SRSF2 (12.7%), ASXL1 (11.4%), and DNMT3A (10.1%), which is consistent with a previous report [6].